Overcoming “aspirin resistance” in MPN

Slides:

Advertisements

Similar presentations

RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.

Advertisements

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby,

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.

How I treat recurrent deep-vein thrombosis by Paul A. Kyrle Blood Volume 127(6): February 11, 2016 ©2016 by American Society of Hematology.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing.

Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

TCR-MHC-peptide(s): in vivo veritas

by Timothy P. Hughes, and David M. Ross

Finding a diamond in the (mouse is) rough

by James O. Armitage, and Dan L. Longo

Positioning NK-κB in multiple myeloma

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Rituximab-induced tumor cell agglutination

Tax fingerprint in adult T-cell leukemia

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Critiquing Cryos by Morie Gertz Blood Volume 111(11):

V617F “JAKs” up myeloproliferative signal

Mutagenic potential of temozolomide in bone marrow cells in vivo

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Acute promyelocytic leukemia, microgranular variant

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Ayalew Tefferi, MD, Tiziano Barbui, MD Mayo Clinic Proceedings

by Alexander Röth, Andreas Hüttmann, Russell P

by Ernest Beutler Blood Volume 98(9): November 1, 2001

An actuarial GPS for hemophilic longevity

Taking a leaf from the book of oral tolerance

Successful Treatment of Iron Overload by Phlebotomies in a Patient With Severe Congenital Dyserythropoietic Anemia Type II by W.K. Hofmann, J.P. Kaltwasser,

by Sabah Sallah, and Jim Y. Wan

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

ROCK and Rho(ll) in bone marrow

Blocking VWF platelet binding to treat TTP

Latest lymphoma classification is skin deep

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

J.-P. Stahl Clinical Microbiology and Infection

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka

Ayalew Tefferi, MD Mayo Clinic Proceedings

Ayalew Tefferi, Pierre Noel, Curtis A. Hanson

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

by Ayalew Tefferi, Terra L. Lasho, Paola Guglielmelli, Christy M

by Christine L. Kempton, and Amanda B. Payne

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

Aspirin resistance after coronary artery bypass grafting

by Wendy Lim, Sara K. Vesely, and James N. George

Erratum Experimental Hematology

Treatment versus Transplant for Challenging Hematologic Disorders

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Anti-CD20-IL-21 fusokine: the tail wags the dog

Pure red cell aplasia by Robert T. Means Blood

Patient Tregs express normal levels of suppression.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Initial treatment of CLL: integrating biology and functional status

How I treat essential thrombocythemia

Diastolic dysfunction in sickle cell

Cold agglutinin disease

Presentation transcript:

Overcoming “aspirin resistance” in MPN by Ayalew Tefferi Blood Volume 119(15):3377-3378 April 12, 2012 ©2012 by American Society of Hematology

In vivo aspirin effect at peak and trough time points in healthy subjects and in patients with essential thrombocythemia receiving aspirin once or twice daily. In vivo aspirin effect at peak and trough time points in healthy subjects and in patients with essential thrombocythemia receiving aspirin once or twice daily. Ayalew Tefferi Blood 2012;119:3377-3378 ©2012 by American Society of Hematology